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Abstract
Enhanced expression and activity of cSrc are associated with ovarian cancer progression. Generally, cSrc does not contain activating mutations; rather, its activity is increased in response to signals that affect a conformational change that releases its autoinhibition. In this report, we analyzed ovarian cancer tissues for the expression of a cSrc-activating protein, AFAP-110. AFAP-110
activates cSrc through a direct interaction that releases it from its autoinhibited conformation. Immunohistochemical analysis revealed a concomitant increase of AFAP-110 and cSrc in ovarian cancer tissues. An analysis of the AFAP-110 coding sequence
revealed the presence of a nonsynonymous, single-nucleotide polymorphism that resulted in a change of Ser403 to Cys403. In
cells that express enhanced levels of cSrc, AFAP-110403C directed the activation of cSrc and the formation of podosomes independently of input signals, in contrast to wild-type AFAP-110. We therefore propose that, under conditions of cSrc overexpression, the
polymorphic variant of AFAP-110 promotes cSrc activation. Further, these data indicate a mechanism by which an inherited genetic
variation could influence ovarian cancer progression and could be used to predict the response to targeted therapy.
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Introduction

Materials and Methods

Ovarian cancer, the most lethal gynecologic malignancy, is characterized
by tumor disruption of the ovarian capsule and dissemination and seeding of the pelvic and abdominal cavities [1]. A combination of unreliable
screening techniques, unspecific symptoms, and chemotherapy resistance results in 15,000 mortalities per year in the United States [2].
BRCA1 and BRCA2 are relevant for the disease, and mutations of these
genes are found in approximately 15% of ovarian cancer cases [3,4].
However, most cases consist of inconspicuous associations between inherited susceptibility and the environment. These associations may be
explained by haplotype mapping studies, which predict that singlenucleotide polymorphisms (SNPs) are not inherited independently,
but instead associate with one another, as well as with environmental
stimuli, producing the disease [5]. Whereas SNPs that influence drug
metabolism and cancer-related symptoms are described [6], little is
known about genetic variants that modulate tumorigenesis. Identification of these genes may enhance our understanding of the progression of
neoplasms such as ovarian cancer. In addition, these polymorphisms
may serve as biomarkers that predict susceptibility to cancer or response
to therapy.
One protein contributing to ovarian cancer progression is cSrc. This
tyrosine kinase is overexpressed and activated in ovarian cancer cell
lines and ovarian tumors [7]. cSrc promotes motility and invasion, alteration of adhesion, and epithelial-mesenchymal transition [8,9]. In
addition, cSrc contributes to chemotherapy resistance because inhibiting cSrc restores sensitivity to paclitaxel [10,11]. cSrc activation does
not correlate with intrinsic mutations or SNPs; rather, signals from
growth factors in the tumor microenvironment or intracellular activators of cSrc direct cSrc activation. A few cSrc activators have genetic
variations that potentially modulate cSrc activity [10,11], and these
may eventually serve as biomarkers useful for identifying the tumors
most likely to respond to cSrc inhibition.
One cSrc activator, the actin-filament associated protein of 110 kDa
(AFAP-110) is encoded by a polymorphic gene. The National Center for Biotechnology Information dsSNP database identifies a nonsynonymous C1210G coding substitution in exon 9 that predicts a
serine-to-cysteine change at amino acid 403 (AFAP-110403C ) (http://
www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=60312). AFAP-110,
through its intrinsic multimerization and a carboxy-terminal actinbinding domain, promotes actin filament cross-linking [12,13]. In
addition, AFAP-110 relays signals from protein kinase C α (PKCα)
that activates cSrc [14,15]. These functions are autoinhibited by an
intermolecular interaction between the carboxy-terminal leucine zipper
motif and an amino-terminal pleckstrin homology domain (PH1)
[13,15]. On experimental deletion of the leucine zipper domain
(AFAP-110ΔLzip) or on PKCα activation, AFAP-110 is uninhibited
and facilitates cSrc activation [13,15]. This correlates with trafficking
of activated cSrc to the cell membrane and the formation of the actinrich invasive structures—podosomes [14,16].
To determine whether AFAP-110 is positioned to activate cSrc in
ovarian cancer, we performed immunohistochemical analysis on ovarian
cancer tissues. In doing so, we demonstrated that AFAP-110 exhibited a
concomitant increase in expression with cSrc. Using polymerase chain
reaction (PCR) analysis, we discovered that a polymorphism of AFAP110 was expressed in one-fourth of the population. This polymorphic
variant, AFAP-110403C, activated cSrc and triggered the formation of
podosomes, suggesting that this variant of AFAP-110 may contribute
to the progression of ovarian cancer.

Reagents
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The rabbit anti–human cortactin polyclonal antibody was purchased
from Abcam (Cambridge, MA). The AFAP-110 antibody F1 was
previously characterized [17]. The mouse anti–avian Src monoclonal
antibody (clone EC10) was obtained from Upstate Biotechnology
(Lake Placid, NY). The rabbit anti–human cSrc monoclonal antibody
(clone EG107) was from Novus Biologicals (Littleton, CO). The rabbit
anti–phospho-Src (Tyr416) polyclonal antibody was purchased from
Cell Signaling (Danvers, MA). Alexa Fluor secondary antibodies and
fluorescently labeled phalloidins were purchased from Invitrogen
(Carlsbad, CA). Tetramethylrhodamine isothiocyanate (TRITC)phalloidin was purchased from Sigma (St Louis, MO).

Cell Culture
Mouse embryo fibroblasts (MEFs), MEFs devoid of Src, Yes, and Fyn
(SYF) and SYF cells reexpressing cSrc (SYF-cSrc) were obtained from the
ATCC (Rockville, MD). Cell lines were cultured in high-glucose Dulbecco modified Eagle medium supplemented with 10% fetal calf serum,
2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin.

Study Subjects and Tissue Samples
A total of 280 normal tissues and 124 serous papillary ovarian carcinomas in stage 3 or stage 4 were obtained from the Cooperative
Human Tissue Network, Pediatric Division, Children’s Hospital, Columbus, OH, and from the West Virginia University Pathology Department. Samples were collected before drug treatment and snap-frozen
at −80°C until RNA/DNA extraction was performed. All specimens
were diagnosed and classified by pathologists.

Complementary DNA Preparation and Reverse
Transcription–Polymerase Chain Reaction
From the studied specimens, total cellular RNA was isolated and
purified by hot phenol/chloroform extraction. Purified RNA were
precipitated and dissolved in diethyl pyrocarbonate–treated water.
Through reverse transcription, using the SuperScript Preamplification
System, complementary DNA (cDNA) were generated with oligo-dT
primers from 5 μg of total RNA per sample (Reverse Transcription
System, Promega, Madison, WI). Exon 9 of the AFAP-110 gene, which
contains the SNP for 403C, was amplified by the polymerase chain
reaction (PCR). The primer set used for amplification contained the
sequence of the 6 intron bases and the 20 exon bases that flank each
end of exon 9 (CCGCAGGCTATCTGAACGTGCTCTCC and
TCCTACCTCCAATACTGCAACCTCCT). The PCR conditions
were 95°C for 3 minutes flowed by 40 cycles at 95°C for 30 seconds,
at 58°C for 30 seconds, and at 72°C for 45 seconds and then by 1 cycle
at 72°C for 10 minutes.

DNA Sequencing and Genotyping
PCR products were separated on agarose gel and purified using the
QIAQuick Gel Extraction Kit (Qiagen, Valencia, CA). The purified
fragments were sequenced to identify AFAP-110 mutations using the
CEQ 8000 Genetic Analysis System with GenomeLab DTCS-Quick
Start Kit (Beckman Coulter, Fullerton, CA) and then using ABI Prism
DNA Sequencer with BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) to confirm identified mutations. In
addition, sequence variants were confirmed in duplicate independent
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PCR amplifications and sequencing reactions to ensure that the mutations were not a result of PCR artifact.

Immunohistochemical Methods
Immunohistochemistry (IHC) was performed on 50 serous papillary
ovarian carcinomas that were paraffin-embedded and cut into 5-μmthick sections and mounted on positive charge-coated slides. Tissue
sections were dried overnight in a 45°C oven, then deparaffinized, rehydrated, and subjected to heat-induced epitope retrieval for 2 hours
in 1 mM citrate buffer (pH 6.00) in an 80°C water bath. Endogenous
peroxide activity was blocked with 3% hydrogen peroxide and was
followed by treatment with a serum-free protein blocker to block nonspecific binding. After each step of the immunoreaction except the
protein blocker, sections were rinsed in Tris-buffered saline with Tween.
Tissues were incubated for 2 hours with anti–AFAP-110 antibody (F1,
6 μg/ml) at a dilution of 1:10 or with anti-cSrc (EG107, diluted 1:50)
in 10% normal horse serum. Negative controls (i.e., preimmune serum
or normal rabbit immunoglobulin G) were incubated in 10% normal
horse serum. Sections were incubated with biotinylated secondary link
antibody, followed by treatment with streptavidin peroxidase and staining with diaminobenzidine substrate–chromogen solution. Counterstaining was performed with hematoxylin, followed by a water rinse
and bluing solution. Tissues were then dehydrated and coverslipped.

Plasmid Constructs
Mutagenesis was performed on human AFAP-110 to generate AFAP110403C. AFAP-110 and AFAP-110403C were cloned into pEGFP-C3
(Clontech, Mountain View, CA) as previously described [15]. The
pGEX-6P-1 vector from Amersham Pharmacia Biotech was used to
create fusion proteins expressing the PH2 domain of AFAP as previously
described [13]. The pGexX-6P-1 PH2403C construct was created by
PCR cloning the PH2403C fragment from the pEGFP vector with
BamHI and EcoRI ends and subsequent cloning into the pGEX-6P-1
vector. Human AFAP-110 wild-type and AFAP110403C cDNA were
PCR-amplified and ligated into pFLAG CMV vector using EcoRI and
XhoI sites to generate Flag-tagged AFAP-110.

Immunofluorescence

Transfection of either GFP AFAP-110 or GFP AFAP-110403C into
MEF, SYF, and SYF-cSrc cells for immunofluorescence was carried
out using either Lipofectamine PLUS (Invitrogen, Carlsbad, CA) or
Nucleofector (Amaxa, Walkersville, MD) according to the manufacturer’s specification. Cells were plated on glass coverslips immediately
after transfection or allowed to recover for 24 hours after transfection
and then plated on glass coverslips coated with 10 μg/ml fibronectin
(BD Bioscience, San Jose, CA). Cells were serum starved for 12 hours
before fixation or left untreated as indicated in the Results section.
Fixation, permeabilization, and staining procedures, including antibody dilutions, were performed as previously described [14]. Confocal
images were acquired with a Zeiss LSM 510 microscope with an average slice thickness of 1 μm. Fluorescence channels were sequentially
recorded using the multitrack recording module. Fluorescence images
were obtained with a Zeiss Axiovert 200M microscope (Thornwood,
NY). Images were subsequently analyzed with LSM 510 software,
Adobe Photoshop, and Image J (Rasband, WS, ImageJ, US National Institutes of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/,
1997–2007).
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Quantification of Podosomes
Actin-rich structures at the ventral surface of cells were identified as
podosomes if three podosome markers: AFAP-110, cortactin, and phospho-cSrc colocalized. About 250 to 300 cells from two independent
experiments were analyzed to determine the percentage of cells forming
podosomes. The number of podosomes/cell was also counted from at
least 100 podosome-positive cells, and the distribution of podosomes/
cell was plotted. Student’s t test with Bonferroni adjustment was used to
detect the statistical significance.

Western Blot Analysis and cSrc Activation Assay
Cultures or human ovarian tissue were lysed or homogenized in
radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 2 mM EDTA, 1% NP-40) containing leupeptin, aprotinin, sodium vanadate, EGTA, and phenylmethylsulfonyl fluoride.
Protein concentration was determined by the bicinchoninic acid assay
(Thermo Fisher Scientific, Rockford, IL), and equal amount of proteins
were resolved on SDS-PAGE and transferred to polyvinylidene fluoride.
SYF cells were transfected with either Flag-AFAP-110 or Flag-AFAP110403C, and cSrc cells were transfected using Lipofectamine PLUS
(Invitrogen). Forty-eight hours after transfection, cells were stimulated
and lysed in radioimmunoprecipitation assay buffer. The levels of phosphorylated Y416 cSrc and total cSrc were assessed in the subsequent
Western blot analysis. Antibody dilutions were performed according
to previously described protocols [14].

Molecular Modeling
The PH domain of SKAP-hom (PDB ID no. 1U5E), a SKAP55 homolog and a Src-associated adaptor protein, was used as a structural template to create a homology model of the AFAP PH2-WT domain using
the homology module of Insight II. Accelrys (San Diego, CA) SKAP-hom
was chosen as the best template based on a BLAST server analysis and
fold recognition programs such as PHYRE, 123D+, and FUGUE. A
sequence alignment was created using the Clustal W server, and manual
adjustments were made by integrating secondary structure prediction
data for the PH2-WT domain from the PROF server with the known secondary structure 4of SKAP-hom. The model was then minimized with
1000 steps of steepest descent minimization. The structure was equilibrated for 300 ps using explicit water molecules as solvent. Equilibration
was completed using the sander command of Amber 8. The model was
analyzed to ensure no misfolded regions existed using the Profiles3D
program in Insight II. The sander command of Amber 8 (Amber, San
Francisco, CA) was then used to create a 700-ps trajectory of the protein
domain in explicit water molecules, and a hydrogen bond analysis for
PH2403S was completed using the default parameters of the ptraj hbond
command in Amber 8. This process was repeated for PH2403C.

Lipid Dot-blot
The lipid dot-blot was used to detect interactions between soluble
GST proteins and phospholipids immobilized on nitrocellulose. Lipid
spotted membranes (PIP strips; Echelon Biosciences, Salt Lake City,
UT) were blocked for 1 hour with 0.2% BSA in TBS and incubated
overnight with 0.5 mg/ml recombinant GST protein in TBS. Bound
GST protein was detected with rabbit anti-GST antibody (SigmaAldrich, St Louis, MO).

Preparation of Lipid Vesicles
Large unilamellar lipid vesicles were prepared by the extrusion method
using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and

Translational Oncology Vol. 3, No. 4, 2010
the indicated lipid (Avanti Polar Lipids, Alabaster, AL). Phospholipids
were combined by molar ratio (10% indicated lipid–90% POPC or
100% POPC) in chloroform–methanol–water (60:30:4), dried with a
stream of N2, and evacuated to remove traces of solvent. The residue
was hydrated with Buffer B (50 mM HEPES, pH 7.2, 80 mM KCl,
and 3 mM EGTA) to attain 2 mM lipid sheets when resuspended by
vortex. Samples were subjected to 10 cycles of freeze thaw and then
10 passages through two layers of 0.10 μm polycarbonate filters under
high pressure N2. The resulting large unilamellar lipid vesicles were used
directly for sedimentation assays.
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of the samples, AFAP-110 was overexpressed focally (Figure 1, A and
B), whereas in 86% of samples, cSrc expression was diffuse (Figure 1, C
and D). AFAP-110 expression in blood vessels is observed in Figure 1B.
AFAP-110 and cSrc were not detected in normal ovaries (Figure 2,
A–C ), although blood vessels exhibited AFAP-110 expression (Figure 2A). AFAP-110 was always expressed with cSrc in well-differentiated
tumors (Figure 2, D–F). Further, AFAP-110 and cSrc always colocalized
in desmoplastic regions (Figure 2, G–I). AFAP-110 is overexpressed in
undifferentiated tumor specimens (13 specimens analyzed), but coexpression of AFAP-110 and cSrc was observed in only four of these
specimens (Figure 2, J–L).

Sedimentation Assay for PtdIns Lipids
To detect pleckstrin homology domain protein associated with membrane phospholipids, a sedimentation assay was used. Samples containing 1.7 mM vesicle lipid and 0.025 mM recombinant GST fusion
protein (PH1) were prepared in 150 μl of binding buffer. Samples
were incubated 60 minutes and centrifuged with a Beckman Airfuge
(Beckman Coulter, Brea, CA) for 15 minutes at room temperature.
From each centrifuged sample, 16% of the supernatant and 100%
of the pellet were analyzed by SDS-PAGE. Gels were stained with
SPYRO orange (Invitrogen).
Results

AFAP-110 and cSrc Are Overexpressed in Ovarian Cancer
IHC determined that AFAP-110 and cSrc were overexpressed in 30
and 32 of 33 ovarian cancer samples, respectively (Table W1). In 60%

A SNP in AFAP-110
Genetic variation within AFAP-110 was examined. Analysis of AFAP110 cDNA isolated from the ovarian cancer cell lines OVCAR-3 and
2008 revealed a synonymous SNP (G297A, CCG to CCA) not found
in the A2780, MCAS, or SKOV3 lines. A nonsynonymous SNP
(C1210G, TCT to TGT) identified in exon 9 resulted in a serine-tocysteine (S403C) substitution and was also found in the OVCAR-3
and 2008 cell lines.
Ovarian tissues were screened to determine the prevalence of this nonsynonymous SNP, C1210G. C1210G was identified in 19 (20.9%) of
91 tumor samples and in 9 (21.2%) of 41 tumor-adjacent normal
tissues (Table W2). In addition, the 33 samples used for IHC were
analyzed and revealed the SNP in 9 (27.3%) of 33 samples.
Tissue not associated with cancer was obtained to determine whether
the SNP was enriched in ovarian cancer. C1210G was present in

Figure 1. Focal and diffuse expression patterns of AFAP-110 and cSrc. Ovarian cancer tissues were sectioned and IHC performed with anti–
AFAP-110 (pAb F1) or anti-cSrc antibody (monoclonal antibody EG107) and the intensity of immunolabeling (brown) qualitatively assessed by
a pathologist. Samples that show focal (highly localized) or diffuse immunolabeling that exhibit deep, robust, or weak immunostaining are
shown for comparison, and these types of images represent the assessment of tissue immunostaining shown in Table W1. (A) AFAP-110
expressed strongly in focal areas of the tumor. (B) AFAP-110 expressed weakly in focal areas of the tumor. (C) cSrc expressed strongly and
diffusely throughout the tumor. (D) cSrc expressed weakly and diffusely throughout the tumor.
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Figure 2. Coexpression of AFAP-110 and cSrc in ovarian tumors. Serial sections of normal human ovary tissues, well-differentiated, and
undifferentiated human ovary tissues were immunolabeled for AFAP-110 with pAb F1, cSrc antibody EG107, and hematoxylin and eosin
(H&E) staining as described under Materials and Methods: normal ovary/AFAP-110 (A), normal ovary/cSrc (B), normal ovary/H&E (C), welldifferentiated tumor/AFAP-110 (D), well-differentiated tumor/cSrc (E), well-differentiated tumor/H&E (F), ovarian tumor/AFAP-110 (G), ovarian
tumor/cSrc (H), ovarian tumor/H&E (I), undifferentiated tumor/AFAP-110 (J), undifferentiated tumor/cSrc (K), and undifferentiated tumor/H&E
(L). In comparison to normal human ovaries (A–C), AFAP-110 and cSrc protein are overexpressed and colocalized in well-differentiated tumors
(D–F), as well as desmoplastic regions of human ovarian tumors (G–I). AFAP-110 is overexpressed in undifferentiated tissue specimens (J–L);
however, colocalization with cSrc was variable. All images were captured at a magnification of 100×. As stated in Table W1, 33 ovarian
tumors were analyzed. Of these, 20 were differentiated tumors and 13 were undifferentiated. Six normal ovaries were analyzed.

80 (28.6%) of 280 normal tissues (Table W2). Thus, AFAP-110403C
was not enriched in ovarian cancer.
We analyzed ovarian tumor tissues and adjacent normal tissue to confirm that cSrc was overexpressed in tissues that have either wild-type
AFAP-110 or AFAP-110403C. For comparison, we analyzed the intensity of cSrc expression in SYF cells, which have no Src family kinases
[18], and SYF-cSrc cells, which overexpress cSrc. Western blot analysis
revealed that cSrc expression in tumors approximated that detected in
SYF-cSrc cells (Figure 3A). An antibody that detected both forms of
AFAP-110 indicated a reduction of AFAP-110 expression in adjacent
normal tissues, confirming the overexpression in tumors observed by
IHC (Figure 3B). Overexpression of cSrc in ovarian tumor samples
was also confirmed.

403C Is Located within the PH2 Domain
The serine-to-cysteine (S403C) substitution is located in the second
PH domain (PH2) of AFAP-110. PH domains are characterized by seven
β-strands that are linked by loop regions. These loop regions differ in
length and amino acid composition and therefore confer the differential binding of PH domains to lipids [19–25]. The S403C substitution
occurs in a loop region between the fifth and sixth β-strand (Figure 4).
In AFAP-110, the hydroxyl R-group of Ser403 is predicted to interact
with water 71% of the time (Figure 4B). However, in AFAP-110403C,
the sulfhydryl R-group of Cys403 is not predicted to be an efficient
hydrogen binding partner (36%; Figure 4D), indicating that the
PH403C domain may exhibit differential binding specificity secondary
to changes in structural flexibility.

Translational Oncology Vol. 3, No. 4, 2010

Figure 3. cSrc expression level in ovarian tumors match those levels
detected in SYF-cSrc cells. (A) Fifty micrograms of SYF or SYF-cSrc
cellular lysates or human ovarian tissue lysates was resolved by 8%
SDS-PAGE and transferred to PVDF, and Western blot analysis was
performed with anti-cSrc antibodies. Code numbers for deidentified
patient samples are shown. Five samples had Ser403 encoded on at
least one allele, and five samples had Cys403 encoded on at least one
allele. (B) cSrc and AFAP-110 expression levels are increased in ovarian tumors relative to normal, adjacent tissue. Western blot analysis
with antibodies to AFAP-110 or cSrc of two ovarian tumor samples
(T) and matching, adjacent control tissues (N) from two patient samples (nos. 77 and 82). Patient no. 77 has the AFAP-110 Ser403 wildtype isoform, whereas patient no. 82 has the AFAP-110 Cys403 SNP
on at least one allele.

Polymorphic AFAP-110 Activates cSrc

Clump et al.

281

PH domains participate in protein-protein interactions. For example,
PH domains in pleckstrin and in AFAP-110 (PH1) bind to PKCα
[15,26]. Further, the PH1 domain of AFAP-110 binds to AFAP-110,
stabilizing the AFAP-110 multimer [13]. To determine differential
binding between AFAP-110 and AFAP-110403C, affinity precipitation
assays using GST fusion proteins were performed. GST-PH2 was more
efficient than GST-PH2403C in pulling down AFAP-110 (Figure 5).
CaOV3 cell lysates were used as a negative control because they have
AFAP-110 expression levels that are at or below detection limits [14].
These data indicated that the S403C change may reduce the affinity and
therefore the ability of the PH2 domain to bind to AFAP-110. Pulldown assays using GST-PH2 did not reveal other binding partners (data
not shown).
PH domains are also known to interact with lipids; however, an analysis of the AFAP-110 PH2 domain demonstrated that it does not contain
the conserved basic residues that mediate electrostatic interactions with
negatively charged phospholipids (Figure 4, B and D). A lipid dot-blot
analysis as well as a lipid vesicle sedimentation assay was used to determine whether the GST-PH2 fusion protein would bind phosphoinositides (Figure W1, A and B). Unlike the positive control, the PH domain
from DAPP1 [27], GST-PH2 did not bind to phosphoinositides.

Effects of AFAP-110 403C on Actin Filament Modulation
Affinity precipitation data indicated that the PH2 domain mediates self-association. Earlier work demonstrated that intermolecular
interactions that stabilize self-association had an autoinhibitory effect

Figure 4. Molecular modeling of the PH2 domain. Homology models for AFAP-110 PH2-WT (A and B) and AFAP-110 PH2403C (C and D)
demonstrated that the amino acid change occurs in a loop region between the fifth and sixth β-strand. Performing a hydrogen bond (dashed
black lines) analysis for each structure predicted that AFAP-110 PH2-WT binds to water molecules (solid red lines) 71% of the time, potentially forming a rigid binding region. In contrast, AFAP-110 PH2403C was predicted to bind to water only 36% of the time. Labeled amino acids
occur at coordinates predicted to interact with phospholipid head groups. Intrastrand loops: green; β-strands: blue; α-helix: red.
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Figure 5. Affinity precipitation of AFAP-110 with GST-PH2 and GST-PH2403C. GST affinity precipitation experiment comparing the differential
ability of GST-PH2 and GST-PH2403C to bind AFAP-110 in MEF, SYF, SYF-cSrc, and CaOV3 cell lysates (A). Equal quantities of GST fusion
proteins were used to affinity precipitate AFAP-110 from equal amounts of cell lysates. (A) Western blot analysis with pAb F1 indicate that
GST-PH2 is more efficient in binding AFAP-110 then GST-PH2403C. CaOV3 cells serve as the negative control in these experiments because
this cell line has low to undetectable amount of AFAP-110. Western blots of cell lysates for AFAP-110 (B) and actin loading controls (C) are
also shown.

on AFAP-110 [13]. Because GST-PH2403C is less efficient in binding
to AFAP-110 than GST-PH2 and destabilization of the AFAP-110
multimer correlated with an acquired ability to activate cSrc, we sought
to determine whether AFAP-110403C had the capacity to activate cSrc.
Cotransfection of Flag-tagged AFAP-110 or Flag-tagged AFAP110403C with cSrc into SYF cells confirmed that AFAP-110403C was able
to direct cSrc activation in contrast to wild-type AFAP-110 (Figure 6A).
The SYF cell lines allowed us to determine the effect of AFAP-110 on
cSrc activity in the absence of other Src family members. These data
indicated that AFAP-110403C can activate cSrc in cells under conditions
of dual overexpression.
To further examine the effect of 403C on the function of AFAP-110,
fibroblasts expressing varying levels of cSrc were used. SYF cells do not
express cSrc, MEFs express a low level, whereas SYF-cSrc cells express a
relatively high level of cSrc (Figure 6B). Neither GFP-AFAP-110 nor
GFP-AFAP-110403C affected detectable changes in cellular morphology
in SYF (data not shown) or in MEF cells (Figure 7A). Anti–phospho
cSrcY416, which recognizes phosphorylated tyrosine 416 in active cSrc,
was used to assess cSrc activity. Active cSrc was undetectable in both
SYF and MEF cells. However, in SYF-cSrc cells, GFP-AFAP-110403C
directed cSrc activation and the formation of podosomes (Figure 7B).
Podosome formation was confirmed based on the colocalization of
AFAP-110, actin, and cortactin in punctate structures on the ventral
surface of the cells [28] (Figure 7C). By quantifying the number of cells
exhibiting podosomes and the number of podosomes/cell, we determined that podosome formation was strongly associated with expression of AFAP-110403C in SYF-cSrc cells and that cells expressing
AFAP-110403C had significantly more podosomes/cell than that of cells
expressing only endogenous or overexpressed AFAP-110 (Figure 8).

Discussion
Ovarian cancer results from a combination of inherited and acquired
genetic alterations as well as from environmental influences. Detection
is limited because of inadequate screening and nonspecific symptoms.
Because this leads to a delayed diagnosis, ovarian cancer is the most

lethal gynecologic malignancy. This creates interest in identifying biomarkers that stratify patients into high-risk subgroups, as well as potentially guide the development of individualized therapy. The present
study demonstrates that AFAP-110403C results in activation of cSrc under conditions of overexpression. Therefore, we hypothesize that the
presence and expression levels of AFAP-110403C may have value in predicting risk and treatment strategies for ovarian cancer.

Figure 6. cSrc activity in SYF cells expressing cSrc and AFAP110403C. (A) Flag-tagged AFAP-110 or AFAP-110403C was transfected
into SYF-cSrc cells, and expression levels were detected with antiFlag antibodies. cSrc expression levels and immunoreactivity with
anti-pSrc416 antibodies were determined. (B) Fifty micrograms of
MEF, SYF, or SYF-cSrc cellular lysates was resolved by 8% SDSPAGE and transferred to PVDF, and cSrc was detected with anticSrc antibodies.
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Figure 7. cSrc activation and podosome formation in SYF-cSrc cells expressing AFAP-110403C. (A) MEF cells were transfected with GFPAFAP-110 or GFP-AFAP-110403C and analyzed for activation of endogenous cSrc or changes in actin filament integrity and podosome formation. Bars, 20 μm. (B) SFY-cSrc cells similarly transiently transfected with GFP-AFAP-110 or GFP-AFAP-110403C and immunolabeled with
anti-Src antibody (b and f) and phospho-Src family (Y416) antibody (c and g). Unlike wild-type GFP-AFAP-110, expression of GFP-AFAP110403C resulted in the formation of punctate structures on the ventral surface of the cells enriched for GFP-AFAP-110403C (e) that exhibited
an increase in c-Src phosphorylation at the Y416 position (merged image, h). (C) Punctate structures resulting from the expression of GFPAFAP-110403C were also enriched for actin and cortactin (merged image, q). In contrast, cells expressing wild-type GFP-AFAP-110 maintained
actin filaments and did not exhibit the formation of actin-rich podosomes (j–m). Bars, 10 μm (panels a–d, e–h, n–q) and 20 μm (panels j–m).
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Figure 8. AFAP-110403C directed podosome formation in SYF-cSrc
cells. (A) Podosomes were counted in the transfected cells, and the
percentage of cells expressing podosomes was quantified (*P =
.015, n = 500 cells). (B) The number of podosomes per cell was
quantified. The podosome distribution was determined by comparing
AFAP-110 to AFAP-110403C. Whereas 80% of the cells transfected
with AFAP-110 wild type (empty bars) exhibit between 0 and three
podosomes/cell, cells transfected with AFAP-110403C (hatched bars)
exhibit a broad distribution with greater than 50% exhibiting more
than eight podosomes per cell.

AFAP-110 functions as an actin filament cross-linking protein and
an adaptor protein that relays signals from PKCα that activate cSrc
[13,15,29–31]. Activated cSrc leads to an increase in cell motility and
the production of podosomes, which may be precursors to invadopodia
[14,16]. Because podosome formation requires both cSrc activation and
dynamic changes in actin filament integrity, AFAP-110 may be uniquely
positioned to regulate these two cellular signals. This ability to activate
cSrc and contribute to the formation of invasive structures may be relevant for cancer progression [32].
As AFAP-110 is a cSrc activating protein, this report determined
whether its expression or its genetic variant AFAP-110403C was associated
with ovarian cancer. IHC demonstrated that both AFAP-110 and cSrc
were overexpressed in ovarian cancer. In general, cSrc expression was diffuse, whereas AFAP-110 expression was focal. Interestingly, both AFAP110 and cSrc were always overexpressed together in well-differentiated
tumors and in desmoplastic regions of the tumor. Colocalization in desmoplastic areas may represent dynamic interactions between the host and
the invasive tumor. As cSrc activation correlates with acquisition of the
invasive phenotype [33], we hypothesized that AFAP-110 is positioned
to activate cSrc and therefore promote invasion in these discrete areas.
AFAP-110 was scanned for genetic changes in human ovarian cancer
cell lines by isolating the cDNA of AFAP-110. A SNP was identified
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that affected a nonsynonymous coding change at base pair 1210, changing Ser403 → Cys403. In addition, 124 ovarian tumors were analyzed
and determined to contain the SNP in 22% of the samples. Adjacent,
normal ovarian tissue as well as that obtained from women with no
known history of malignancy revealed a similar SNP profile. Thus, although expression levels of AFAP-110 were elevated in ovarian cancer,
the presence of the SNP was not enriched in tumors. Therefore, this
study focused on determining whether high expression levels of
AFAP-110 or AFAP-110403C affected differences in cSrc activation or
cell morphology.
Serine 403 of AFAP-110 is positioned on the loop between the fifth
and sixth β-strands of the PH2 domain. Molecular modeling indicated
that the peripherally positioned R-hydroxyl group of Ser403 forms hydrogen bonding with H2O 71% of the time, whereas the Cys403 forms
hydrogen bonding with H2O less efficiently (36%). Hydrogen bonds
may stabilize the loops of the PH domain and increase the rigidity in
the binding pocket.
There are as many as 258 different proteins that contain PH domains [34,35]. Of these, only 10% are predicted to facilitate phospholipid binding by forming interactions between positively charged
Lys or Arg residues within the PH binding pockets and the negatively
charged phospholipids. The PH2 domain of AFAP-110 is unable to
bind phospholipid.
PH domains also bind to proteins. Affinity precipitation revealed that
similar to the PH1 domain, the PH2 domain also bound AFAP-110.
Thus, it is predicted that the PH2 domain may foster either intramolecular or intermolecular interactions, promoting multimerization or stabilization of the multimer. However, GST-PH2403C bound less efficiently
to AFAP-110. Loss of AFAP-110 multimer stability correlated with a
gain-of-function, including an ability to colocalize and activate cSrc
[13,14,16]. Thus, we sought to determine whether AFAP-110403C activates cSrc.
Expression of AFAP-110 or AFAP-110403C in MEF cells, which contain detectable levels of cSrc, estimated around 20,000 molecules per cell
(D.C. Flynn, unpublished observations), did not result in cSrc activation or morphologic changes that are associated with cSrc activation.
Ectopically expressed AFAP-110 or AFAP-110403C in SYF-cSrc cells,
which overexpress cSrc at levels that are higher than MEFs, was used
to determine whether AFAP-110403C has a differential capacity to activate cSrc. Compared with AFAP-110, AFAP-110403C was a more efficient activator of cSrc and was more efficient in inducing the formation
of podosomes. Thus, these data indicate that in cells overexpressing cSrc,
AFAP-110403C more efficiently activates cSrc compared with wild-type
AFAP-110. Previous evidence suggested that, in chicken embryo fibroblasts transformed by the Rous sarcoma virus, only 5% of AFAP-110 is
complexed with v-Src [31]. Because only a subset of AFAP-110 and Src
interact, it is possible that, in MEF cells, only 5% or less of the cSrc
population that is expressed would be engaged with AFAP-110403C
and that this stoichiometry of binding could be below detection. Further, if 5% of cSrc were activated in MEF cells, activation may be insufficient to direct morphologic changes characteristic of Src-transformed
cells. Thus, under conditions where both cSrc and AFAP-110403C expression is low, as in normal tissues, cSrc activation is unlikely to occur or
affect cellular changes even in those cells that inherit AFAP403C. Under
conditions of dual overexpression of AFAP-110403C and cSrc, AFAP110403C may independently activate cSrc and promote tumor progression. Because AFAP-110 and cSrc are overexpressed in the same tumors,
AFAP-110 may enhance cSrc activation by receiving input signals that
enable cSrc activation, or alternatively, AFAP-110403C may result in a
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reduced capacity to self-associate resulting in the independent activation
of cSrc. Although not enriched in ovarian cancer tumors, the 403C
variant may lead to a more aggressive and metastatic disease through
its promotion of cSrc activation in those tumors in which it is found.
Future studies using ovarian cancer cell lines and additional patient samples should address this issue. These data also indicate a mechanism by
which an inherited genetic variation could influence ovarian cancer progression and could be used to predict the response to targeted therapy.
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Table W1. Summary of IHC Intensity and Pattern of cSrc and AFAP-110 Expression in 33 Ovarian
Tumor Samples.
Tumor Sample

F/D (AFAP)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
Negative
Positive
D/S
D/W
F/S
F/W
Diffuse
Focal

0
F
F
0
F
F
F
F
D
F
D
D
F
F
F
F
D
F
0
F
D
D
F
D
D
D
F
D
D
F
F
F
D

S/W (AFAP)
0
S
W
0
W
W
W
S
S
S
W
S
S
S
W
S
S
W
0
W
S
S
S
S
S
S
S
S
S
S
W
S
S
3
30
11
1
10
8
12
18

F/D (Src)
D
D
D
D
D
D
D
D
D
D
D
F
D
0
D
D
F
D
F
D
D
D
D
D
F
D
D
F
D
D
D
D
D

S/W (Src)
S
W
W
S
W
S
W
S
S
W
W
S
S
0
W
W
W
S
W
W
W
W
S
W
S
W
W
W
S
W
W
W
W
1
32
9
18
2
3
27
5

91%

40%
60%

D, diffuse immunostaining; F, focal immunostaining; S , strong intensity; W, weak intensity.

Table W2. Presence of C1209G Nonsynonymous SNP in Tissue Samples.
Sample

CC (Wild Type)

CG SNP (One Allele)

GG SNP (Both Alleles)

Total SNP (One or Two Alleles)

Tumor (GoG)
Tumor (WVU)
Tumor (total)
Normal tissue

72/91 (79.1%)
24/33 (72.8%)
97/124 (78.2%)
200/280 (71.4%)

18/91
7/33
24/124
73/280

1/91
2/33
3/124
7/280

19/91
9/33
27/124
80/280

(19.8%)
(21.2%)
(19.3%)
(26.1%)

(1.1%)
(6.1%)
(2.4%)
(2.5%)

(20.9%)
(27.3%)
(21.7%)
(28.6%)

Exon 9 was amplified from 124 ovarian cancer tissue samples and 280 normal tissues. Sequence analysis was performed, and the presence of the wild-type sequence (C on both alleles — CC) or the SNP
(G on one allele — CG) or on both alleles (GG) was calculated. In tumor-adjacent normal ovarian tissues, the nonsynonymous SNP was identified in 9 (21.2%) of 41 samples obtained from GoG.
WVU indicates West Virginia University.

Figure W1. The PH2 domain does not bind to phospholipids. (A) Lipid dot-blot analysis was used to examine the ability of the GST-AFAPPH2 domain to bind immobilized phospholipids. GST-DAPP1-PH was used as a positive control and bound both PtdIns-3,4-P2 and PtdIns3,4,5-P3 consistent with published data [36]. The GST-AFAP-110-PH2 did not bind any immobilized phosphoinositides tested. (B and C) A
lipid vesicle sedimentation assay was performed with GST-PH2 (B) or the positive control GST-DAPP1-PH (C). After SDS-PAGE of the supernatants (S) and the pellets (P), the gels were stained with SYPRO orange. Data are consistent with the lipid dot-blot analysis.

